Orexigen Therapeutics, Inc.  

(Public, NASDAQ:OREX)   Watch this stock  
Find more results forOREX
1.64
-0.01 (-0.61%)
Real-time:   3:42pm GMT-5
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.57 - 1.67
52 week 1.39 - 9.37
Open 1.67
Vol / Avg. 645,785.00/1.55M
Mkt cap 238.53M
P/E     -
Div/yield     -
EPS -0.40
Shares 145.44M
Beta 2.22
Inst. own 78%
Feb 23, 2016
Q4 2015 Orexigen Therapeutics Inc Earnings Release (Estimated) - 4:00pm GMT-5 - Add to calendar
Feb 11, 2016
Orexigen Therapeutics Inc at Leerink Partners Global Healthcare Conference
Feb 9, 2016
Orexigen Therapeutics Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference
Jan 14, 2016
Orexigen Therapeutics Inc at JPMorgan Healthcare Conference
Dec 2, 2015
Orexigen Therapeutics Inc at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -111.70% -67.59%
Operating margin -109.75% -54.99%
EBITD margin - -54.74%
Return on average assets -20.06% -19.09%
Return on average equity -212.72% -116.89%
Employees 47 -
CDP Score - -

Address

3344 N Torrey Pines Ct Ste 200
LA JOLLA, CA 92037-1024
United States - Map
+1-858-8758600 (Phone)
+1-858-8758650 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity. The Company's product is Contrave, a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER. The Company's product Contrave, is approved in the United States by the United States Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI), of around 30 kilograms per square meter (kg/m2) or greater (obese), or around 27 kilograms per square meter or greater (overweight) in the presence of at least one weight-related comorbid condition. The Company also submitted an application for marketing authorization with the European Medicines Agency (EMA) for Contrave under the name Mysimba.

Officers and directors

Eckard Weber M.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Michael A. Narachi President, Chief Executive Officer, Interim Chief Financial Officer, Director
Age: 55
Bio & Compensation  - Reuters
Thomas P Lynch Executive Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
Thomas Cannell Executive Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Preston S. Klassen M.D. Senior Vice President, Head of Global Development
Age: 46
Bio & Compensation  - Reuters
Chris Hazuka Acting General Counsel
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 50
Bio & Compensation  - Reuters
Brian H. Dovey Independent Director
Age: 73
Bio & Compensation  - Reuters
David J. Endicott Independent Director
Age: 50
Bio & Compensation  - Reuters
Peter K. Honig M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters